Knott David M Jr purchased a new position in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 420,000 shares of the company's stock, valued at approximately $651,000. Knott David M Jr owned approximately 0.16% of Autolus Therapeutics at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new stake in Autolus Therapeutics during the fourth quarter worth about $26,000. Barclays PLC grew its holdings in Autolus Therapeutics by 1,094.3% during the fourth quarter. Barclays PLC now owns 11,859 shares of the company's stock worth $28,000 after acquiring an additional 10,866 shares during the period. Invesco Ltd. grew its holdings in Autolus Therapeutics by 53.3% in the first quarter. Invesco Ltd. now owns 32,738 shares of the company's stock valued at $51,000 after purchasing an additional 11,381 shares during the period. Virtus ETF Advisers LLC grew its holdings in Autolus Therapeutics by 29.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company's stock valued at $62,000 after purchasing an additional 6,081 shares during the period. Finally, OMERS ADMINISTRATION Corp acquired a new stake in Autolus Therapeutics in the fourth quarter valued at approximately $85,000. Institutional investors own 72.83% of the company's stock.
Autolus Therapeutics Price Performance
Shares of AUTL stock traded down $0.09 on Friday, hitting $1.77. The stock had a trading volume of 1,754,147 shares, compared to its average volume of 1,800,670. The firm has a market capitalization of $469.74 million, a P/E ratio of -2.10 and a beta of 1.90. Autolus Therapeutics PLC Sponsored ADR has a 1 year low of $1.11 and a 1 year high of $5.00. The company's 50 day moving average price is $2.33 and its 200-day moving average price is $1.90.
Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.06. The company had revenue of $13.50 million for the quarter, compared to analyst estimates of $12.92 million. On average, equities analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.94 EPS for the current year.
Wall Street Analysts Forecast Growth
Several analysts have commented on AUTL shares. Wells Fargo & Company dropped their price objective on Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating on the stock in a report on Wednesday. Needham & Company LLC reaffirmed a "buy" rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, July 21st. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Autolus Therapeutics currently has an average rating of "Buy" and an average target price of $9.12.
View Our Latest Report on AUTL
About Autolus Therapeutics
(
Free Report)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Recommended Stories
Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
